The Safety and Efficacy of Dexloxiglumide for the Relief of Symptoms of Functional Dyspepsia.

Forest Laboratories

Status and phase

Completed

Phase 2

Conditions

Dyspepsia

Treatments

Drug: dexloxiglumide

Drug: Nexium (esomeprazole)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00303264

DEX-MD-20

Details and patient eligibility

About

"Functional dyspepsia" has been defined loosely as "pain or discomfort centered in the upper abdomen." The symptoms can also include fullness, early satiety, bloating, belching, nausea, retching and vomiting. These symptoms may present with or without the co-existence of symptoms of heartburn or gastroesophageal reflux disease (GERD). Functional dyspepsia is a diagnosis of exclusion in which other disease states, such as ulcer, cancer, etc. are ruled out and the source of the pain is unknown.

The standard of care for most patients presenting with dyspeptic symptoms has been with proton pump inhibitors (PPI), regardless of whether or not the patient's symptoms include acid-related conditions, e.g., heartburn, GERD, etc. Although PPI treatment has yielded some success in these patients, there is a significant population of patients whose dyspeptic symptoms are not adequately treated with PPI's alone.

The purpose of this study is to evaluate the use of dexloxiglumide in the treatment of the symptoms of functional dyspepsia in patients whose dyspeptic symptoms are not being treated adequately with PPI's.

Enrollment

48 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Be male or female, 18 to 75 years of age, inclusive.
Must understand English and be able to follow the instructions about completing the diary and questionnaires.
At the time of Screening, have pain and/or discomfort in your upper abdomen for at least one day each week in the last month.
At the time of Screening, have at least one other symptom of FD for at least one day each week in the last month.

Exclusion criteria

Have a known hypersensitivity to dexloxiglumide, any PPI, or aluminum/magnesium-containing antacids
Have a history of organic diseases, structural or biochemical, of the gastrointestinal system that can cause dyspepsia.
Have active irritable bowel syndrome (C-IBS, alt-IBS, D-IBS).
Have findings leading to a clinical suspicion of other secondary causes of dyspepsia, including endocrine, metabolic and neurological disorders.
Have a body mass (BMI) value of greater than 38 (applies to both males and females).
Have been enrolled in a previous investigational study of dexloxiglumide.
Have received treatment with any investigational drug within a 30-day period, or 5 half-lives, whichever is longer, prior to study entry.
Use or dependence on "prohibited" medications at study entry.